leadf
logo-loader
viewAnteris Technologies Ltd

Admedus extends successful distribution deal for medication delivery pumps

The company’s shares are in trading halt since August 2, 2018, pending news of a capital raising.

ambIT infusion product
Products that deliver better outcomes for patients

Admedus Ltd (ASX:AHZ) has renewed its exclusive distribution agreement with Utah-based Summit Medical Products Inc for a further eight years.

The updated arrangement confirms the long-standing relationship between the two companies, which began in 2007, and secures a key component of Admedus’ infusion supply chain.

Under the terms of the extended agreement, Admedus remains the exclusive distributor of Summit’s ambIT® infusion products in Australia and New Zealand until 2026.

The range of ambIT infusion pumps are suitable for the delivery of medications and pain relief.

 

Admedus head of infusion Glenn Gilchrist said: “Admedus has enjoyed a long and successful partnership with Summit Medical and we are delighted to renew this commitment for another eight years.

“Our team is proud to represent Summit’s range of innovative ambIT products that deliver better outcomes for patients and add significant value to our infusion portfolio.”

READ: Admedus has capital raising news imminent, granted ASX trading halt

The company’s shares are in trading halt since August 2, 2018, pending news of a capital raising.

Admedus expects the suspension to last until the earlier of the commencement of normal trading on August 13, 2018,  or the release of an announcement by the company.

READ: Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

Last month, the company signed an exclusive distribution agreement with Medical Instruments S.p.A. to market and distribute its clinically-superior ADAPT® technology in Italy.

Under the agreement, Medical Instruments will initially distribute Admedus’ non-toxic and non-calcifying flagship ADAPT bio-scaffold CardioCel®.

The bio-scaffold is used to repair congenital heart deformities and more complex heart defects. It is also used to reconstruct dysfunctional heart valves and valve leaflets.

Quick facts: Anteris Technologies Ltd

Price: 4 AUD

ASX:AVR
Market: ASX
Market Cap: $23.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read